EECP improves markers of functional capacity regardless of underlying ranolazine therapy by Ziad, Sanaz et al.
University of the Pacific 
Scholarly Commons 
School of Pharmacy Faculty Articles Thomas J. Long School of Pharmacy 
1-1-2020 
EECP improves markers of functional capacity regardless of 
underlying ranolazine therapy 
Sanaz Ziad 
University of the Pacific 
Jamil Malik 
Methodist Texsan Hospital 
Obinna Isiguzo 





See next page for additional authors 
Follow this and additional works at: https://scholarlycommons.pacific.edu/phs-facarticles 
 Part of the Biochemistry, Biophysics, and Structural Biology Commons, Chemicals and Drugs 
Commons, and the Pharmacy and Pharmaceutical Sciences Commons 
Recommended Citation 
Ziad, S., Malik, J., Isiguzo, O., Xu, L., Chen, L., Cox, A., & Shah, S. (2020). EECP improves markers of 
functional capacity regardless of underlying ranolazine therapy. American Journal of Cardiovascular 
Research, 10(5), 593–601. 
https://scholarlycommons.pacific.edu/phs-facarticles/360 
This Article is brought to you for free and open access by the Thomas J. Long School of Pharmacy at Scholarly 
Commons. It has been accepted for inclusion in School of Pharmacy Faculty Articles by an authorized 
administrator of Scholarly Commons. For more information, please contact mgibney@pacific.edu. 
Authors 
Sanaz Ziad, Jamil Malik, Obinna Isiguzo, Lang Xu, Leqi Chen, Annette Cox, and Sachin Shah 
This article is available at Scholarly Commons: https://scholarlycommons.pacific.edu/phs-facarticles/360 
Am J Cardiovasc Dis 2020;10(5):593-601
www.AJCD.us /ISSN:2160-200X/AJCD0123235
Original Article 
EECP improves markers of functional capacity  
regardless of underlying ranolazine therapy 
Sanaz Ziad1, Jamil Malik2, Obinna Isiguzo2, Lang Xu3, Leqi Chen3, Annette Cox3, Sachin A Shah1,3
1Department of Pharmacy Practice, Thomas J Long School of Pharmacy, University of The Pacific, Stockton, CA, 
USA; 2Cardiologist, Methodist Texsan Hospital, San Antonio, TX, USA; 3Flow Therapy, Fort Worth, TX, USA 
Received September 27, 2020; Accepted December 8, 2020; Epub December 15, 2020; Published December 30, 
2020
Abstract: Objective: Enhanced external counterpulsation (EECP) and ranolazine are approved treatments for pa-
tients with chronic stable angina by the United States Food and Drug Administration (FDA). Whether EECP offers 
clinical benefits regardless of underlying ranolazine therapy needs further investigation. Methods: This was a ret-
rospective evaluation of patients referred to a specialized EECP center. Patients having data on 6-Minute Walk 
Distance (6MWD) or Duke Activity Status Index (DASI) were categorized into two groups (EECP with ranolazine or 
EECP only). The primary endpoints were change in 6MWD and DASI before and after a full course of EECP within 
each of the two groups. Inter-group differences were also assessed. The Wilcoxon test was utilized to compare 
the change from baseline within each group and the Mann-Whitney U test to compare difference between groups. 
Results: A total of 2836 patient records (age 66.9 ± 10 years) were identified (1193 in EECP and ranolazine group 
and 1643 in EECP only group). EECP added to baseline ranolazine resulted in a statistically significant improvement 
in 6MWD and DASI (+126 feet (IQR: 230 feet), and +13.35 (IQR: 17.11), respectively, P<0.001 for both). Similarly, 
the EECP only group showed a statistically significant improvement in 6MWD and DASI (+140 feet (IQR: 225 feet) 
and +13.49 (IQR: 18.02), respectively, P<0.001 for both). There was no statistically significant difference between 
the two groups when comparing the change from baseline in 6MWD and DASI score (P=0.256 and P=0.056 respec-
tively). Conclusion: EECP improves markers of functional capacity regardless of baseline ranolazine therapy. EECP’s 
unique safety profile advocates for its early consideration in the treatment algorithm. 
Keywords: EECP, ranolazine, chronic stable angina, functional capacity, quality of life 
Introduction
In the United States, 9.4 million people over 
the age of 20 suffer from angina [1]. Class I 
recommendations for the management of ch- 
ronic stable angina (CSA) include pharmaco-
logic interventions such as beta-adrenergic 
blockers, calcium channel blockers, and nit- 
rates along with invasive modalities including 
percutaneous coronary interventions (PCI) and 
coronary artery bypass grafts (CABG) [2]. Des- 
pite optimized pharmacotherapy and surgical 
interventions, refractory angina affects an es- 
timated 600000 to 1.8 million people within 
the United States with an approximate 50000 
to 100000 newly diagnosed cases each year 
[3]. This population has a high incidence of 
hospitalization secondary to their burden of 
disease with an estimated average cost of 
$10080 per hospitalization [4].
Ranolazine is approved by the United States 
Food and Drug Administration (FDA) as add-on 
therapy to Class I agents for the treatment of 
CSA (Class IIa, level B) [2, 5]. Enhanced exter- 
nal counterpulsation (EECP) is an FDA appro- 
ved non-invasive device for treatment of pa- 
tients with chronic stable angina or heart fail-
ure (Class IIb, level B) [2]. A full course of EECP 
therapy typically consists of 1-hour sessions 5 
days per week for 7 weeks, totaling 35 ses-
sions [2, 6]. 
EECP treatment is relatively well tolerated with 
side effects primarily related to device use [7]. 
Multiple studies have found that EECP impro- 
ves markers of functional capacity such as 
6-Minute Walk Distance (6MWD) and Duke 
Activity Status Index (DASI) [8, 9]. While these 
results are promising, they are limited by small 
study populations (under 200 patients) and 
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have yet to explore the isolated degree of ben-
efit from EECP when added to baseline ranola-
zine therapy [10]. EECP therapy is one of only 
two guideline supported non-pharmacologic 
treatment modalities that mechanistically im- 
proves myocardial perfusion to relieve symp-
toms of refractory angina [11]. With the generic 
availability of ranolazine as of February 2019 
and emerging data supporting the clinical use 
of non-pharmacologic treatments like EECP, 
understanding the magnitude of benefit EECP 
has when added to ranolazine therapy is par-
ticularly warranted [11, 12]. The intent of our 
study was to investigate whether EECP offers 




This retrospective analysis was approved by 
the Institutional Review Board at the University 
of the Pacific. All patients receiving care at 
Flow Therapy clinics with a diagnosis of angina 
from April 2013 to October 2018 with data on 
6MWD and DASI were eligible for inclusion in 
the analysis (n=2836 records). 
Patients were allocated into either the EECP 
and ranolazine (EECP+R) or EECP only groups 
according to baseline ranolazine usage. Pa- 
tients were included if they had pre- and post-
data on 6MWD or DASI. Data was extracted 
from the outpatient clinic’s electronic health 
record with a Python script (Python version 
3.7) written to extract the following data: pa- 
tient identification, age, gender, comorbidities, 
baseline medications, pre- and post-6MWD 
(feet), pre- and post-DASI, and baseline CCS 
angina class. 
The pre-specified primary endpoints were ch- 
anges from baseline in 6MWD and DASI after a 
full course of EECP treatment in patients with 
and without ranolazine therapy. The 6MWD is 
validated measurement of exercise functional 
capacity commonly used to assess responses 
to medical interventions in patients suffering 
from chronic cardiovascular and pulmonary dis-
eases [13, 14]. The 6MWD is a strong predictor 
of cardiovascular events in patients with stable 
coronary heart disease and an independent 
measure of morbidity and mortality amongst 
patients suffering from congestive heart failure 
and chronic obstructive pulmonary disease 
[11, 15]. The test measures the distance pati- 
ents are able to walk on a flat, hard surface in 
a duration of 6 minutes and is a predictor of 
health outcomes in stable coronary heart dis-
ease, heart failure, pulmonary hypertension, 
and pulmonary disease [13, 14]. The DASI is a 
validated 12 item questionnaire used to mea-
sure health-related quality of life specific to 
cardiovascular functional status [12-14]. The 
questionnaire provides independent prognos- 
tic information for long-term adverse clinical 
events in stable cardiac patients, as well as an 
indicator of mortality in patients with chronic 
heart failure [15-17]. Due to the retrospective 
nature of this analysis, all patients treated with 
a full course of EECP and not on baseline rano-
lazine therapy were considered as a compara-
tor group. 
Patients who visited the center for multiple 
treatment courses were included in the overall 
analysis. Patients not completing at least 30 
EECP sessions were excluded from analyses. A 
sensitivity analysis was performed to assess 
changes in the primary endpoints in patients 
having gone through only 1 full course (1 
round) of EECP, having a baseline Canadian 
Cardiovascular Society (CCS) angina class ≥3 
or with heart failure. 
Statistical analysis 
We performed the Wilcoxon test to compare 
the change from baseline within each group 
(intra-group) and the Mann Whitney U-test was 
utilized to compare the changes from baseline 
in the EECP+R and EECP only groups (inter-
group). A P<0.05 was considered statistically 
significant. A Fisher’s exact was performed to 
assess differences in categorical variables. All 
data are represented as median and interquar-
tile range. All analysis was done using Python 
script (Python version 3.7).
Results
Baseline demographics 
A total of 2836 patient records were identi- 
fied having available data for 6MWD or DASI 
(1193 (42.1%) in the EECP+R group and 1643 
(58.0%) patients in the EECP only group). Of 
those enrolled 2312 unique patients complet-
ed only one course of EECP. Overall, patients 
were predominantly male (70.0%) with an aver-
Functional capacity changes in EECP and ranolazine
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age age of 66.9 ± 10. Of the patients includ- 
ed 98.2% had coronary artery disease (CAD), 
36.6% had heart failure, 46.3% had diabetes, 
83.2% had concomitant hyperlipidemia, and 
89.9% had hypertension. Nearly 42.0% (n= 
1193) of the overall cohort were on ranolazine 
therapy at baseline (Table 1). 
Outcomes in EECP+R Group 
Post EECP therapy, all patients on baseline 
ranolazine (EECP+R group) showed a statisti-
cally significant improvement in 6MWD (+126 
ft (IQR 230), P<0.001) and DASI (+13.35 (IQR 
17.11), P<0.001). When limiting the model to 
patients completing 1 round only, statistical- 
ly significant improvements were shown in 
6MWD (+125 ft (IQR 230), P<0.001) and DASI 
(+13.5 (IQR 18.45), P<0.001). Further, patients 
with a CCS angina class ≥3 also demonstrat- 
ed significant improvements in 6MWD (+130 
ft (IQR 230), P<0.001) and DASI (+13.44 (IQR 
17.04), P<0.001). Likewise, when limited to 
patients with heart failure, results maintained 
significance for each of the study end points 
(6MWD +135 ft (IQR 249), P<0.001 and DASI 
+11.49 (IQR 16.25), P<0.001). Figures 1 and 2 
describe the change in 6MWD and DASI for the 
EECP+R and EECP only groups. 
Outcomes in EECP only group 
The EECP only cohort similarly showed a statis-
tically significant improvement in 6MWD (+140 
ft (IQR 225), P<0.001) and DASI (+13.49 (IQR 
18.02), P<0.001). In participants completing 1 
round only, improvements in 6MWD (+140 ft 
(IQR 225), P<0.001) and DASI (+13.56 (IQR 
18.45), P<0.001) were also statistically signifi-
cant. Statistical significance was maintained 
when limiting analysis to CCS angina class of 
≥3 (6MWD +140 ft (IQR 225), P<0.001 and 
DASI +13.49 (IQR 18.01), P<0.001). Similarly, 
improvements in 6MWD (+135 ft (IQR 235), 
P<0.001) and DASI (+11.69 (IQR 17.85), P< 
0.001) were statistically significant when limit-
ed to patients with heart failure. 
Outcomes comparing EECP+R vs. EECP only 
groups 
There were no statistically significant differ- 
ences for 6MWD and DASI between the EE- 
CP+R and EECP only groups (P=0.2560 and 
P=0.0558 respectively) (Table 2). This was 
true across all subgroups for both endpoints 
(all p-values >0.05). 
Discussion
Our findings indicate EECP therapy improves 
markers of functional capacity regardless of 
baseline ranolazine therapy. These benefits 
were maintained after limiting the analysis to 
participants completing only 1 course of EECP, 
having CCS angina class of ≥3, or having heart 
failure.
The magnitude of change for 6MWD (>125 
ft) is clinically meaningful. Generally, improve-
ments ranging from 82 ft (25 m) to 229 ft (70 
m) in 6MWD are associated with enhanced 




Average Age 66.0 ± 11 67.6 ± 10
Male 838 (70%) 1144 (70%)
CABG 715 (60%) 818 (50%)
PCI 396 (33%) 522 (32%)
CAD 1174 (98%) 1612 (98%)
Diabetes 591 (50%) 722 (44%)
Heart Failure 385 (32%) 654 (40%)
Hyperlipidemia 997 (84%) 1363 (83%)
Hypertension 1091 (92%) 1459 (89%)
Myocardial Infarction 591 (50%) 760 (46%)
6MWD 1175 ± 381 1105 ± 390
DASI 9.7 ± 10 10.3 ± 15
ACE Inhibitors 412 (35%) 540 (33%)
ARB 310 (30%) 402 (25%)
Alpha blockers 39 (3%) 44 (3%)
Aspirin 988 (83%) 1236 (75%)
Blood Thinner† 790 (66%) 945 (56%)
Beta blockers 956 (80%) 1246 (76%)
Calcium Channel Blockers 342 (29%) 421 (26%)
Digoxin 28 (2%) 56 (3%)
Diuretics 439 (37%) 683 (42%)
Nitrates 994 (83%) 974 (59%)
Omega Fatty Acids 213 (18%) 232 (14%)
Statins 988 (83%) 1280 (78%)
ACE inhibitor, Angiotensin-Converting Enzyme Inhibitor; ARB, 
Angiotensin II receptor blockers; 6MWD, 6-Minute Walk 
Distance; CABG, Coronary Artery Bypass Grafts; CAD, Coro-
nary Artery Disease; CCS, Canadian Cardiovascular Society; 
DASI, Duke Activity Status Index; EECP, Enhanced External 
Counterpulsation; EECP+R, EECP and Ranolazine Group; PCI, 
Percutaneous Coronary Interventions. †including antiplatelet 
agents (ticagrelor and prasugrel) and direct oral anticoagu-
lants (apixaban and rivaroxaban). 
Functional capacity changes in EECP and ranolazine
596 Am J Cardiovasc Dis 2020;10(5):593-601
clinical outcomes and mortality benefits [13, 
18, 19]. A study conducted by Beatty et al 
found that in patients with stable coronary 
heart disease, each standard deviation reduc-
tion in 6MWD (341 ft [104 m]) was associated 
DASI scores. A prospective analysis of 13 
patients with chronic stable angina found that 
after completion of a full course of EECP thera-
py there were marked improvements in DASI 
scores (12 ± 2 vs. 19 ± 3; P=0.03) [9]. 
Figure 1. Improvement from baseline in 6MWD for EECP+R and EECP only. 
Patients in the EECP+R group showed a statistically significant improve-
ment in 6MWD of +126 ft (IQR 230) with P<0.001 from baseline. Likewise, 
patients in the EECP only group showed a statistically significant improve-
ment from baseline in 6MWD of +140 ft (IQR 225) with P<0.005. The in-
tergroup analysis between the two groups was not statistically significant 
(P>0.05). Abbreviations: 6MWD, 6-Minute Walk Distance; EECP, Enhanced 
external counterpulsation; EECP+R, EECP and ranolazine.
Figure 2. Improvement from baseline in DASI for EECP+R and EECP only. 
Patients in the EECP+R group had a statistically significant improvement 
from baseline DASI score of +13.35 (IQR 17.11) with P<0.001. Patients in 
the EECP only cohort also showed a statistically significant improvement 
in DASI of +13.49 (IQR 18.02) with a P<0.001. Intergroup analysis did not 
show a statistically significant difference in improvement in DASI (P>0.05). 
Abbreviations: DASI, Duke Activity Status Index; EECP, Enhanced external 
counterpulsation; EECP+R, EECP and ranolazine.
with a 54% higher risk of death 
(age-adjusted HR 1.54, 95% CI 
1.32-1.80) and a 55% increa- 
sed risk of any cardiovascular 
event (age-adjusted HR 1.55, 
95% CI 1.35-1.78) [14].
The improvement in DASI in 
both groups was approxima- 
tely 13 points. A change of 
4-6 points in DASI score is 
associated with improved clini-
cal outcomes [20-22]. A stu- 
dy evaluating the prognostic 
value of the DASI on 1700 sta-
ble, non-acute coronary syn-
drome patients with heart fail-
ure found that DASI scores in 
the lowest quartile were at a 
3.3 fold increased risk in 5 
year mortality as compared to 
the highest score quartile (HR 
3.33, 95% CI 2.57-4.36, P< 
0.0001) [23]. 
Our results parallel previous 
findings showing EECP’s inde-
pendent improvement in mark-
ers of functional capacity. A 
prospective, longitudinal pilot 
study by Wu et al, assessed 
changes from baseline in 6M- 
WD 6 months post EECP thera-
py in 34 patients with refracto-
ry angina. They found 6MWD 
improved from 1345 ft (410 m) 
at baseline to 1440 ft (439 m) 
(P<0.01) post treatment (+95 
ft (29 m)). The change evident 
in our EECP only group is high-
er than that observed by Wu et 
al; this may be due to our 
patient population being at a 
lower baseline functional ca- 
pacity, the low sample size in 
the study by Wu et al, or better 
EECP care provided by the par-
ticular centers in our analyses 
[8]. EECP has also shown inde-
pendent positive effects on 
Functional capacity changes in EECP and ranolazine
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For comparison, ranolazine added to standard 
of care therapy improves 6MWD and DASI by 
37.7 ft (11.5 m) (992.5 ft (302.5 m) ± 423.2 ft 
(129.0 m) baseline to 1030.2 ft (314.0 m) ± 
418.3 ft (127.5 m) at 12 months) and 3.8 po- 
ints (18.7 ± 14.9 baseline to 22.5 ± 15.8 at 12 
months) respectively. These results were not 
found to be statistically significant for either 
endpoint [24, 25]. 
The magnitude of benefit seen in our results 
can be explained by the fact that ranolazine 
and EECP have differing mechanisms of ac- 
tion. EECP’s mechanism of action is similar to 
an intra-aortic balloon pump where inflation 
and deflation of the pneumatic cuffs during 
diastole and systole are synchronized to heart 
rhythm. This results in an increase in coronary 
diastolic pressure and improved oxygen supp- 
ly with retrograde aortic blood [26]. It is postu-
lated that benefits observed with EECP the- 
rapy may be secondary to development of new 
collateral blood vessels, improved endothelial 
function and vascular reactivity, and enhanced 
ventricular function [17, 27-29]. In contrast, 
ranolazine is a piperazine derivative that inhib-
its late sodium channels in myocardial tissue. 
While the exact mechanism of action of ranola-
zine is not fully realized, it has been known to 
impede myocardial sodium overload leading to 
improved myocardial relaxation, reduced ven-
tricular rigidity, and subsequent improved myo-
cardial perfusion [30]. Ranolazine does not 
appear to effect heart rate or blood pressure 
[31]. Our findings are not too surprising as ba- 
sed on a recent meta-analysis from the Coch- 
rane Library, ranolazine add-on therapy only 
improved angina frequency and did not pro- 
vide any mortality or quality-of-life benefits 
[32].
To our knowledge, this is the largest analysis 
comparing the addition of EECP to ranolazine 
and raises the question of EECP’s role in the 
treatment of refractory angina. Elective surgi-
cal revascularization is a high cost and inva- 
sive procedure that while proven to improve 
coronary ischemia, does not provide superior 
results to medical optimization. In the Clini- 
cal Outcomes Utilizing Revascularization and 
Aggressive Drug Evaluation trial (COURAGE), 
PCI added to optimized medical therapy did 
not reduce the risk of death or myocardial 
infarction in patients with objective myocardial 
ischemia and coronary artery disease in com-
parison to patients receiving only optimized 
medical therapy [33]. In the Bypass Angioplas- 
ty Revascularization Investigation 2 Diabetes 
study (BARI 2D), CABG or PCI added to opti-
mized medical therapy was found to be equiva-
lent to optimized medical therapy in reducing 
the risk of death or major adverse cardiovascu-
lar events (MACE) (death, MI, or stroke) [34]. 
The Percutaneous Coronary Intervention in 
Stable Angina trial compared PCI to placebo in 
medically optimized patients with angina. The 
study found that PCI did not improve treadmill 
exercise time as compared to placebo (16.6 s, 
95% CI -8.9-42, P=0.20) [35]. 
More recently, in the landmark study Interna- 
tional Study of Comparative Health Effective- 
ness with Medical and Invasive Approaches 
(ISCHEMIA) 5179 participants with stable isch-
emic heart disease and moderate or severe 
ischemia on stress imaging or severe ischemia 
based on non-imaging exercise tolerance test-
Table 2. Change in markers of functional capacity
Population N Change in EECP+R, Median (IQR) N Change in EECP Only, Median (IQR) P-value
6MWD (feet) 
    All Patients 1104 126 (230) 1545 140 (225) 0.256
    Round 1 Only 859 125 (230) 1305 140 (225) 0.173
    ≥3CCS 1033 130 (230) 1401 140 (225) 0.425
    HF Only 350 135 (249) 609 135 (235) 0.203
DASI
    All Patients 900 13.35 (17) 1279 13.49 (18) 0.056
    Round 1 Only 728 13.50 (18) 1122 13.56 (18) 0.130
    ≥3CCS 845 13.44 (17) 1164 13.49 (18) 0.061
    HF Only 293 11.49 (16) 499 11.69 (17) 0.330
CCS, Canadian Cardiovascular Society; DASI, Duke Activity Status Index; EECP, Enhanced external counterpulsation; EECP+R, 
EECP and ranolazine; HF, heart failure; IQR, Interquartile Range; 6MWD, 6-Minute Walk Distance. 
Functional capacity changes in EECP and ranolazine
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ing were randomized to receive optimal medi-
cal therapy or invasive surgical revasculariza-
tion. The study results showed that initial inva-
sive intervention, as compared to optimized 
medical therapy, did not demonstrate a reduc-
tion in the study’s primary end point of time 
to cardiovascular death, MI, hospitalization for 
unstable angina, heart failure or resuscitated 
cardiac arrest (Adjusted HR invasive vs. con- 
servative 0.93 (0.80, 1.08); P=0.34) [33]. In 
our analysis we found that even patients on 
baseline ranolazine had clinical benefits from 
the addition of EECP. Our results further sup-
port the early consideration of EECP for patients 
with stable ischemic heart disease. As such, 
it is plausible that EECP may provide enough 
benefits to eliminate the addition of further 
pharmacotherapeutic options in a population 
with a pre-existing high pill burden.
Medication non-adherence in patients with car-
diovascular disease varies from 24% to 60%, 
and as a result one potential drawback to rano-
lazine use in patients with refractory angina is 
that treatment requires long term medication 
adherence [36-39]. Similarly, compliance with 
the 35 sessions of EECP is not feasible for all 
patients. However, after a full course of EECP 
clinical benefits have been known to sustain 
for up to 2 years. A long-term clinical outcomes 
trial showed sustained reductions in CCS angi-
na class in 55% of patients presenting at the 
two year follow up [6]. While medication optimi-
zation remains the primary treatment for angi-
na, using EECP earlier in the treatment algo-
rithm can be a clinically astute strategy in 
patients especially due to its safety profile and 
having nearly no contraindications. This appli-
cation warrants further exploration in future 
studies.
Though our data suggests that EECP provides 
clinically meaningful improvements indepen-
dent of baseline ranolazine use, several limita-
tions need to be considered. While this is the 
largest analysis of this kind, interpretation is 
limited by the retrospective study design and 
lack of propensity score matching. We could 
not control for background antianginal therapy 
or medication dose optimization. Since this 
data was extracted from an outpatient clinic, 
without access to complete medical records, 
advanced statistical techniques that control for 
confounding variables could not be utilized. As 
such, we accounted for baseline differences 
between the EECP+R and EECP only groups by 
comparing the change from baseline rather 
than the unadjusted absolute values for each 
endpoint. Future studies would benefit from a 
ranolazine only arm for comparison. 
Conclusion
EECP improves clinically relevant endpoints of 
6MWD and DASI by over 125 ft and 13 points 
respectively. This observed benefit was inde-
pendent of baseline ranolazine therapy. The 
observed clinical benefit of EECP is likely dri- 
ven by its different mechanism of action rela-
tive to ranolazine. EECP should be considered 
earlier in management of angina and ischemic 
heart disease independent of or complimenta-
ry to ranolazine therapy as a result of its supe-
rior safety profile, relatively high compliance 
and sustained long-term benefits.
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